European Parliament · 10 October 2019

Commission Implementing Regulation (EU) 2019/707 of 7 May 2019 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances alpha-cypermethrin, beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, desmedipham, dimethoate, dimethomorph, diuron, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, foramsulfuron, formetanate, metalaxyl-m, methiocarb, metribuzin, milbemectin, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole, s-metolachlor and tebuconazole

Adopted

402 in favour · 222 against · 39 abstained. 663 members voted.

What it asks for, in the Parliament's words

Calls on the Commission to withdraw the approvals for substances if proof or reasonable doubt exists that they will not meet the safety criteria laid down in Regulation (EC) No 1107/2009
Considers that Commission Implementing Regulation (EU) 2019/707 does not respect the precautionary principle
Considers that Commission Implementing Regulation (EU) 2019/707 exceeds the implementing powers provided for in Regulation (EC) No 1107/2009

Quoted from B9-0103/2019, which says more than these lines. Each is a whole paragraph; this site does not rewrite them.